Blood test may replace tissue biopsies for ovarian cancer monitoring
NCT ID NCT04511988
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study looks at whether a simple blood test (liquid biopsy) can track how ovarian cancer changes over time, instead of taking multiple tissue samples. Twenty newly diagnosed patients will give blood and tissue samples during their treatment for up to two years. The goal is to see if the amount of DNA in the blood can predict if the cancer comes back, spreads, or leads to death.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could show that a simple blood test can monitor ovarian cancer changes, potentially reducing the need for repeated tissue biopsies.
What could go wrong
This is a very small pilot study with only 20 patients, so results may not apply to everyone. It is designed to test feasibility, not to prove a new treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut de Cancerologie de Lorraine
Vandœuvre-lès-Nancy, 54506, France